Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

BACKGROUND: Pazopanib is an angiogenesis inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Post hoc analysis of a clinical trial demonstrated a relationship between pazopanib trough concentrations (C(min)) and treatment efficacy. The aim of this study was to explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Verheijen, R. B., Swart, L. E., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., Steeghs, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686255/
https://www.ncbi.nlm.nih.gov/pubmed/29051995
http://dx.doi.org/10.1007/s00280-017-3463-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686255/
https://www.ncbi.nlm.nih.gov/pubmed/29051995
http://dx.doi.org/10.1007/s00280-017-3463-x

Ejemplares similares